Eli Lilly Reports P-III (SURMOUNT-3 & 4) Studies Results of Tirzepatide for the Treatment of Obesity and Overweight
Shots:
- The 2 P-III studies evaluating tirzepatide vs PBO in 806 & 783 adults. Both trials met all primary & secondary objectives
- For the efficacy and treatment regimen estimand in both studies, (21.1% & 6.7%) and (18.4% & 5.5%) reduction in body weight over 72wks. & from randomization at 36-88wks. vs (3.3% over 72wks. & 14.8%) and (2.5% & 14.0%) weight regain for PBO; total mean body weight reduction after 12wks. of lifestyle intervention to 72wks. of treatment & over the entire 88wk. period was 26.6% & 26.0% and 24.3% & 25.3%
- In both estimand, 94.4% & 87.5% achieved an additional ≥5% body weight reduction from randomization vs 10.7% & 16.5% in PBO over 72wks. in (SURMOUNT-3) study. The safety profile was similar to prior trials and to that of incretin-based therapies
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports P-III Trial (SURMOUNT-2) Results of Tirzepatide for Obesity or Overweight and Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
